oral, ultralong-acting insulin analog

effective in Ph. IIa, hum. t1/2~3 d, 4% F dog

albumin-binding motif + reduced endocytosis

J. Med. Chem., Dec. 28, 2020

Novo Nordisk, Maaloev, DK

Novo oral insulin analog

 this content is exclusive to
Premium members

Upgrade to a Premium Drug Hunter membership to unlock the full content and start reading now.